Trial Profile
A Single-Arm, Multicenter Phase 2 Study of BGB-A317 in Patients With Previously Treated PD-L1+ Locally Advanced or Metastatic Urothelial Bladder Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Tislelizumab (Primary)
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 18 Feb 2023 Results assessing LM correlate with survival outcomes and the tumor immune microenvironment in UBC patients treated with tislelizumab in the BGB-A317-204 trial presented at the 2023 Genitourinary Cancers Symposium
- 13 Apr 2022 Samples from three pooled phase 1/2 studies (NCT02407990, NCT04068519, NCT04004221) assessing between ICs and the clinical efficacy of tislelizumab (TIS), an anti-programmed cell death protein 1 monoclonal antibody, by examining tumor tissues from various tumor types presented at the 113th Annual Meeting of the American Association for Cancer Research
- 02 Jun 2021 Status changed from active, no longer recruiting to completed.